Adverts

Open Access Articles- Top Results for Aptazapine

Aptazapine

</th></tr>
Aptazapine
200px
Systematic (IUPAC) name
2-methyl-1,3,4,14b-tetrahydro-2H,10H-pyrazino[1,2-a]pyrrolo[2,1-c][1,4]benzodiazepine
Clinical data
Identifiers
71576-41-5 7pxN
None
PubChem CID 51355
ChemSpider 46513 7pxY
UNII 240J927J1R 7pxY
KEGG D02972 7pxY
ChEMBL CHEMBL336712 7pxY
Chemical data
Formula C16H19N3
253.34 g/mol
 14pxN (what is this?)  (verify)

Aptazapine (CGS-7525A) is a tetracyclic antidepressant (TeCA) which was assayed in clinical trials for the treatment of depression in the 1980s but was never marketed.[1][2][3] It is a potent α2-adrenergic receptor antagonist with ~10x the strength of the related compound mianserin and has also been shown to act as a 5-HT2 receptor antagonist and H1 receptor inverse agonist, while having no significant effects on the reuptake of serotonin or norepinephrine.[1][4] Based on its pharmacological profile, aptazapine may be classified as a noradrenergic and specific serotonergic antidepressant (NaSSA).

See also

References

  1. ^ a b Liebman JM, Lovell RA, Braunwalder A et al. (January 1983). "CGS 7525A, a new, centrally active alpha 2 adrenoceptor antagonist". Life Sciences 32 (4): 355–63. PMID 6131367. doi:10.1016/0024-3205(83)90081-4. 
  2. ^ Author Unknown (1985). Annual Reports in Medicinal Chemistry (Volume 20). Boston: Academic Press. p. 352. ISBN 0-12-040520-2. 
  3. ^ David J. Triggle (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN 0-412-46630-9. 
  4. ^ Gower AJ, Broekkamp CL, Rijk HW, Van Delft AM (1988). "Pharmacological evaluation of in vivo tests for alpha 2-adrenoceptor blockade in the central nervous system and the effects of the enantiomers of mianserin and its aza-analog ORG 3770". Archives Internationales De Pharmacodynamie Et De Thérapie 291: 185–201. PMID 2896489.